Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Efocipegtrutide

INVESTIGATIONAL

GLP-1, GIP and glucagon receptor triple agonist

0
graded results
2
ongoing records
0
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 0

Efocipegtrutide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Metabolic dysfunction-associated steatohepatitis; Subcutaneous injection; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Registered or protocol records without results

These records remain discoverable, but they are not counted or presented as results.

Efocipegtrutide INVESTIGATIONAL
Liver and MASH Decrease REGISTERED, NO RESULTS
Very low evidence

Efocipegtrutide (HM15211, Hanmi) is a long-acting GLP-1/GIP/glucagon triple co-agonist developed primarily for MASH/NASH rather than obesity. In a phase 1b/2a study it...

Abdelmalek MF et al. HM-TRIA-201: phase 2 study of HM15211 (efocipegtrutide) in biopsy-co... Source
Full findingEfocipegtrutide (HM15211, Hanmi) is a long-acting GLP-1/GIP/glucagon triple co-agonist developed primarily for MASH/NASH rather than obesity. In a phase 1b/2a study it significantly reduced liver fat and body weight in obese subjects with NAFLD; a phase 2 biopsy-confirmed NASH trial (HM-TRIA-201) followed.
PopulationPhase 1b/2a multicentre randomised placebo-controlled in obese subjects with NAFLD. Phase 2 HM-TRIA-201: adaptive randomised double-blind 52-week study, N=217 biopsy-confirmed NASH.
Fundingindustry - Hanmi (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Efocipegtrutide INVESTIGATIONAL
Liver and MASH Not directional REGISTERED, NO RESULTS
Very low evidence

Efocipegtrutide (HM15211; Hanmi, GLP-1/GIP/glucagon TRIPLE) is the closest published triple-agonist comparator to retatrutide for MASH, but its phase-2 histology trial...

Abdelmalek MF et al. Phase 2 52-week study of HM15211 in biopsy-confirmed NASH - design (... Source
Full findingEfocipegtrutide (HM15211; Hanmi, GLP-1/GIP/glucagon TRIPLE) is the closest published triple-agonist comparator to retatrutide for MASH, but its phase-2 histology trial (HM-TRIA-201) exists only as a PROTOCOL paper - no histologic outcome results published. The triple's MASH-resolution endpoint remains UNREAD in humans.
PopulationHM-TRIA-201 (protocol): planned N=217, biopsy NASH/MASH, adaptive RCT, 52 wk; primary = resolution without worsening fibrosis. Results pending.
Fundingindustry - Hanmi (trial sponsor; inferred from registration trial)
Comparatorsplacebo